Surface treatment of indomethacin agglomerates with Eudragit

被引:11
作者
Bajdik, J
Pintye-Hódi, K
Planinsek, O
Tüske, Z
Tasic, L
Regdon, G
Srcic, S
Eros, I
机构
[1] Univ Szeged, Dept Pharmaceut Technol, H-6720 Szeged, Hungary
[2] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia
[3] Univ Belgrade, Dept Pharmaceut Technol & Cosmetol, Belgrade, Serbia
基金
匈牙利科学研究基金会;
关键词
agglomerates; coating; Eudragit NE; indomethacin; surface free energy;
D O I
10.1081/DDC-120030932
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Indomethacin is a widely used anti-inflammatory drug with serious side-effects. This drug was used as a model drug for the coating of agglomerates with a permeable film (Eudragit NE). The agglomeration of the crystals increased the flowability of the bulk crystals. The coating further improved the flowability, and also the uniformity of the mass of the filled capsules. The coating film also influenced the wetting of the samples. The coating decreased the surface free energy and therefore reduced the adhesion forces between both the dry and the wet particles. The modification of the flow properties and the even capsule filling can be explained by this phenomenon. Since coating film does not dissolve in the artificial gastric juice, the dissolution test was performed only in the artificial intestinal juice. The dissolution of indomethacin from the coated sample was changed significantly. Accordingly, coating of the crystals can be performed in order to protect the mucosa of the gastrointestinal tract or to promote the preparation of solid dosage form.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 1992, INTERMOLECULAR SURFA
[2]  
Bajdik J, 2001, PHARM IND, V63, P1197
[3]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[4]   Can the organization of a binary mix be predicted from the surface energy, cohesion parameter and particle size of its components? [J].
Barra, J ;
Lescure, F ;
Falson-Rieg, F ;
Doelker, E .
PHARMACEUTICAL RESEARCH, 1998, 15 (11) :1727-1736
[5]   1-ethylazacycloalkan-2-one indomethacin esters as new oral prodrugs: chemical stability, enzymatic hydrolysis, anti-inflammatory activity and gastrointestinal toxicity [J].
Bonina, F ;
Trombetta, D ;
Borzi, A ;
DePasquale, A ;
Saija, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 156 (02) :245-250
[6]  
BUCKTON G, 1995, INTERFACIAL PHENOMEN, P59
[7]  
Cole G., 1995, PHARM COATING TECHNO, P9
[8]   INTESTINAL PERFORATION ASSOCIATED WITH OSMOTIC SLOW RELEASE INDOMETHACIN CAPSULES [J].
DAY, TK .
BRITISH MEDICAL JOURNAL, 1983, 287 (6406) :1671-1672
[9]  
Deák D, 1999, STP PHARMA SCI, V9, P525
[10]   Use of extrusion-spheronization to develop an improved oral dosage form of indomethacin [J].
Deasy, PB ;
Law, MFL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 148 (02) :201-209